Skip to main content

PMD-026 (RSK1 Inhibitor)

Therapeutic RSK1 Targeting in Myelofibrosis

  • RegistryNCT07379125
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMyelofibrosis
  • SponsorWashington University School of Medicine
How PMD-026 worksNCT073791251 min

What the film says

Read the transcript

This trial is for adults with myelofibrosis, a bone marrow cancer.

The idea: PMD-026 is a pill taken every twelve hours that blocks RSK1, a protein called ribosomal protein S6 kinase A1. Two dose levels are tested, then more patients are added at the chosen dose.

The study looks for the recommended dose, then at how well it works.

This phase 1 study plans 18 patients. At Washington University School of Medicine in St. Louis, Amy Zhou leads it.

Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

PMD-026 is an oral drug which will be taken every 12 hours on an outpatient basis at the assigned dose every day of each 28-day cycle. Provided by Phoenix Molecular Designs.

The study

How the trial runs.

This is a phase Ib study evaluating PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), in participants with myelofibrosis (MF).The dose escalation portion utilizes a standard 3+3 design to evaluate two dose levels with an additional dose de-escalation portion to identify the recommended phase II dose (RP2D); subsequently, an additional 6 patients will be enrolled in the dose expansion portion evaluating the efficacy of PMD-026.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically confirmed diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis in chronic phase, according to the 2016 WHO criteria
  • Patients must have had at least 1 prior JAK inhibitor treatment for a minimum of 12 weeks and their disease was determined resistant or refractory, and/or their response was lost or intolerant to treatment.
  • Intermediate-2 or High-risk MF, as defined by the Dynamic International Prognostic Scoring System (DIPSS).
  • Splenomegaly defined as estimated spleen volume of ≥450 cm3 by imaging with either MRI, CT or ultrasound, or a palpable spleen >=5 cm from the costal margin.
  • Baseline MFSAF v4.0 Total Symptom Score ≥ 10

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.